CTOs on the Move

ViaCyte

www.viacyte.com

 
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.viacyte.com
  • 3550 General Atomics Court
    San Diego, CA USA 92121
  • Phone: 858.207.0500

Executives

Name Title Contact Details
Steven White
Chief Technology Officer Profile

Funding

ViaCyte raised $10M on 09/25/2018
ViaCyte raised $80M on 11/29/2018
ViaCyte raised $53.9M on 04/22/2021

Similar Companies

Just-Evotec Biologics

Just Evotec Biologics is an integrated design company that delivers advanced biotherapeutics discovery, CDMO capabilities and FIH to commercial manufacturing. They focus on accelerating and expanding access to biotherapeutics through scientific and tec...

Oxyband Technologies

Oxyband Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Takeda Oncology

Takeda Oncology,, is a biopharmaceutical company based in Cambridge, Massachusetts.

Hatec Inc

Hatec Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NGM Biopharmaceuticals

NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio`s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.